Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020

MenB-FHBp was licensed in Europe in 2017 from the age of 10. In the “postmarketing life” of a new vaccine, surveillance of Adverse Events Following Immunization (AEFI) is crucial, to better understand the pattern of safety and the effectiveness. This paper describes the MenB-FHBp AEFIs notified in P...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanizzi, Pasquale, Bianchi, Francesco Paolo, Martinelli, Andrea, Di Lorenzo, Antonio, De Petro, Paola, Graziano, Giusi, Lattanzio, Sabrina, Diella, Giusy, Stella, Paolo, Ancona, Domenica, Tafuri, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Meningococcal – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009947/
https://www.ncbi.nlm.nih.gov/pubmed/35201942
http://dx.doi.org/10.1080/21645515.2022.2041359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009947/
https://www.ncbi.nlm.nih.gov/pubmed/35201942
http://dx.doi.org/10.1080/21645515.2022.2041359

Ejemplares similares